- Home
- MNKD vs NBXG Comparison
MNKD vs NBXG Comparison
Compare MNKD & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNKD | NBXG |
|---|---|---|
| Founded | 1991 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNKD | NBXG |
|---|---|---|
| Price | $3.95 | $15.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $7.97 | N/A |
| AVG Volume (30 Days) | ★ 3.7M | 105.0K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $348,966,000.00 | N/A |
| Revenue This Year | $27.07 | N/A |
| Revenue Next Year | $13.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $2.23 | $12.32 |
| 52 Week High | $6.51 | $17.43 |
Technical Indicators
Market Signals| Indicator | MNKD | NBXG |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 59.63 |
| Support Level | $3.77 | $14.87 |
| Resistance Level | $4.29 | $16.94 |
| Average True Range (ATR) | 0.21 | 0.29 |
| MACD | 0.05 | 0.05 |
| Stochastic Oscillator | 90.05 | 94.17 |
Price Performance
Historical ComparisonAbout MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.